293 filings
Page 2 of 15
8-K
g9xlui
28 Dec 22
Other Events
8:10am
8-K
vldmemt
22 Dec 22
Other Events
8:17am
8-K
ya2w7y0 odcyzc4ok0w
14 Nov 22
Acasti Pharma Reports Second Quarter 2023 Operational Results
7:15am
8-K
yff 5xjk0dst112d
30 Sep 22
Acasti Announces Court Dismissal of Stockholder Litigation
4:08pm
8-K
kxy6rwd
29 Sep 22
Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders
9:26am
8-K
6hi80v
11 Aug 22
Acasti Pharma Reports First Quarter 2023 Operational Results
7:05am
8-K
lgoa 26dohoaq2co
29 Jul 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:01pm
8-K
b50bb de7v
21 Jun 22
Results of Operations and Financial Condition
8:10am
8-K
h1vjf1
18 May 22
Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, with Intravenous GTX-104 Meeting All Endpoints
7:37am
8-K
79h0jjya fu
25 Mar 22
Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors
7:36am
8-K
1j9xpk8kc37oqc
14 Feb 22
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022
7:10am
8-K
ijqdnxp4bkct
2 Dec 21
Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104
7:17am
8-K
zphi91swa5p
15 Nov 21
Acasti Pharma Announces Annual Stock Option Grants
12:00am
8-K
n5gb8dfsl12 jm4qyv
10 Nov 21
Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022
7:09am
8-K/A
0tf0a6 r9z0czsqb
5 Nov 21
Financial Statements and Exhibits
4:07pm
8-K
p0ok2oz89z 7t99
22 Sep 21
Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards
8:30am
8-K
gelbyb6md 37qpx32
9 Sep 21
Amendments to Articles of Incorporation or Bylaws
4:19pm
8-K
7lqy70 xz1fx07pui
27 Aug 21
Completion of Acquisition or Disposition of Assets
8:47am
8-K
b17le 3i0voexfb
12 Aug 21
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022
10:57am
8-K
idl5fa7 1dt
23 Jul 21
Other Events
8:43am